Goldman Sachs analyst Paul Choi upgraded Esperion Therapeutics to Neutral from Sell with an unchanged price target of $50. The analyst continues to believe Esperion's sole asset, bempedoic acid, is approvable but that near term sales are "likely to underwhelm" ahead of expected cardiovascular outcomes data. However, he thinks the stock now reflects more tempered expectations for bempedoic acid. His 2023 to 2025 sales estimates remain 45%-60% below consensus. Further, the data that has been amassed in recent months generally supports bempedoic acid's overall efficacy and safety profile ahead of the FDA decision to accept the new drug application filings, Choi tells investors in a research note.